Notably, we uncovered driver genes in pediatric AML, including mutations in LZTR1 (n = 2) and SPOP (n = 1), which have not been previously associated with pediatric AML, as well as loss of function mutations in ARID2 (n = 2) and SH2B3 (n = 2), which have been reported as pathogenic in other pediatric cancers, like ALL, but not in AML. This evidence concerns the gene SH2B3 and acute myeloid leukemia.